SK-N-SH Transfection Reagent (Neuroblastoma Cells, HTB-11)

Altogen Biosystems is a quality producer and custom research organization for genetic research. Custom biological products and other experiments include siRNA screening, optimization of preclinical research, stable transfection of cells, RNAi testing and more. Dedicated to benefiting researchers with state-of-the-art and specialized services, Altogen Biosystems aims to further modern clinical discoveries. Visit Altogen Biosystems’ catalog for custom brain cancer xenograft models .

Derived from the metastasized neuroblastoma of a young human female, the SK-N-SH cell line is one of the primary in vitro models for brain cancer drug development and testing of novel immunotherapies. With neurite outgrowths and modulated differentiation, SK-N-SH complement dopamine-beta-hydroxylase expression with a physiology that closely follows that of live neuroblastoma tissue in vivo . With cancer-specific transfection reagents , research involving the screening of siRNA sequences can show how RNA interference technology could be used to combat cancer proliferation even after metastasis.

The SK-N-SH cell line was isolated in 1970 from the brain tissue extracted from a 4-year-old female patient suffering from a neuroblastoma. These cells are ideal as transfection hosts because they are known to express high levels of dopamine-beta-hydroxylase and having a higher doubling time. SK-N-SH are used in biomedical research for certain types of brain cancer. Altogen Biosystems  manufactures and prepares a SK-N-SH transfection reagent that is cationic lipid based with a high transfection efficacy. This reagent is proven to establish stable cell lines for reliable yields.   Transfection Reagent for SK-N-SH Cells (Neuroblastoma Cells, HTB-11)